As filed with the Securities and Exchange Commission on June 30, 2016
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Histogenics Corporation
(Exact name of Registrant as specified in its charter)
| | |
| Delaware | | 04-3522315 |
(State or Other Jurisdiction of Incorporation or Organization) | | (IRS Employer
Identification No.) |
830 Winter Street, 3rd Floor
Waltham, Massachusetts 02451
(781) 547-7900
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2013 Equity Incentive Plan
(Full title of plans)
Jonathan Lieber
Chief Financial Officer
830 Winter Street, 3rd Floor
Waltham, Massachusetts 02451
(Name and address of agent for service)
(781) 547-7900
(Telephone number, including area code, of agent for service)
Please send copies of all communications to:
Marc F. Dupré, Esq.
Albert W. Vanderlaan, Esq.
Gunderson Dettmer Stough
Villeneuve Franklin & Hachigian, LLP
One Marina Park Drive, Suite 900
Boston, Massachusetts 02210
Telephone: (617) 648-9100
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
| Large accelerated filer | | ¨ | | Accelerated filer | | ¨ |
| | | |
| Non-accelerated filer | | ¨ (Do not check if a smaller reporting company) | | Smaller reporting company | | x |
CALCULATION OF REGISTRATION FEE
| | | | | | | | |
|
Title of Securities to be Registered | | Amount to be Registered(1) | | Proposed Maximum Offering Price Per Share(2) | | Proposed Maximum Aggregate Offering Price(2) | | Amount of Registration Fee |
Common Stock, $0.01 par value per share | | | | | | | | |
—2013 Equity Incentive Plan | | 300,000 | | $1.76 | | $528,000.00 | | $53.17 |
TOTAL | | 300,000 | | | | $528,000.00 | | $53.17 |
|
|
| (1) | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s Common Stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s Common Stock, as applicable. |
| (2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and (h)(1) under the Securities Act. The offering price per share and aggregate offering price for the unissued stock options and shares of Common Stock are based upon the average of the high and low prices of the Registrant’s common stock as reported on The NASDAQ Stock Exchange Global Market on June 27, 2016. |
EXPLANATORY NOTE
Information Required in the Section 10(a) Prospectus
Pursuant to General Instruction E to Form S-8 under the Securities, this Registration Statement is filed by Histogenics Corporation (the “Company”) for the purpose of registering additional shares of Common Stock under the Company’s 2013 Equity Incentive Plan, as amended (the “EIP”).
On June 22, 2016, the Company’s stockholders approved an amendment to the EIP to increase the number of shares of Common Stock available for issuance under the EIP by 300,000 shares and increase the number of shares of Common Stock automatically added to the EIP on January 1 of each year during the term of the EIP, starting with January 1, 2017 (the “EIP Amendment”). Following adoption of the EIP Amendment, the number of shares of Common Stock available for issuance under the EIP is subject to an automatic annual increase on the first day of the Company’s calendar year beginning in 2017 equal to the lesser of (a) 4.0% of the total number of shares of Common Stock outstanding on December 31 of the prior year or, (b) the number determined by the Company’s Board of Directors. This Registration Statement registers the 300,000 additional shares of Common Stock available for issuance under the EIP as a result of the EIP Amendment.
Of the 1,196,957 shares currently authorized by the EIP, 896,957 have already been registered pursuant to the currently effective Registration Statements on Form S-8 (Registration Nos. 333-201552 and 333-210075) filed on January 16, 2015 and March 3, 2016, respectively (together, the “Original Registration Statement”). The contents of the Original Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated herein by this reference. Any items in the Original Registration Statement not expressly changed hereby shall be as set forth in the Original Registration Statement.
I-1
PART II
Information Required in the Registration Statement
| | | | | | | | | | | | |
Exhibit Number | | Exhibit Description | | Incorporated by Reference | | Filed Herewith |
| | | Form | | File No. | | Exhibit | | Filing Date | |
| | | | | | |
| 5.1 | | Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. | | | | | | | | | | X |
| | | | | | |
| 10.3 | | 2013 Equity Incentive Plan. | | 8-K | | 001-36751 | | 10.3 | | May 4, 2016 | | |
| | | | | | |
| 10.3A | | Amendment No. 1 to 2013 Equity Incentive Plan. | | | | | | | | | | X |
| | | | | | |
| 23.1 | | Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm. | | | | | | | | | | X |
| | | | | | |
| 23.2 | | Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (contained in Exhibit 5.1). | | | | | | | | | | X |
| | | | | | |
| 24.1 | | Power of Attorney (incorporated by reference to the signature page of this Registration Statement). | | | | | | | | | | X |
II-1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on this 30th day of June, 2016.
|
| HISTOGENICS CORPORATION |
|
/s/ Jonathan Lieber |
| Jonathan Lieber |
| Chief Financial Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Histogenics Corporation, a Delaware corporation, do hereby constitute and appoint Adam Gridley and Jonathan Lieber, and each of them, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| | | | |
Signature | | Title | | Date |
| | |
/s/ Adam Gridley Adam Gridley | | Chief Executive Officer, President and Director (Principal Executive Officer) | | June 30, 2016 |
| | |
/s/ Jonathan Lieber Jonathan Lieber | | Chief Financial Officer (Principal Financial and Accounting Officer) | | June 30, 2016 |
| | |
/s/ Garheng Kong, M.D., Ph.D. Garheng Kong, M.D., Ph.D. | | Chairman of the Board | | June 30, 2016 |
| | |
/s/ Joshua Baltzell Joshua Baltzell | | Director | | June 30, 2016 |
| | |
/s/ David Gill David Gill | | Director | | June 30, 2016 |
| | |
/s/ John H. Johnson John H. Johnson | | Director | | June 30, 2016 |
| | |
/s/ Michael Lewis Michael Lewis | | Director | | June 30, 2016 |
| | |
/s/ Kevin Rakin Kevin Rakin | | Director | | June 30, 2016 |
EXHIBIT INDEX
| | | | | | | | | | | | |
Exhibit Number | | Exhibit Description | | Incorporated by Reference | | Filed Herewith |
| | | Form | | File No. | | Exhibit | | Filing Date | |
| | | | | | |
| 5.1 | | Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. | | | | | | | | | | X |
| | | | | | |
| 10.3 | | 2013 Equity Incentive Plan. | | 8-K | | 001-36751 | | 10.3 | | May 4, 2016 | | |
| | | | | | |
| 10.3A | | Amendment No. 1 to 2013 Equity Incentive Plan. | | | | | | | | | | X |
| | | | | | |
| 23.1 | | Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm. | | | | | | | | | | X |
| | | | | | |
| 23.2 | | Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (contained in Exhibit 5.1). | | | | | | | | | | X |
| | | | | | |
| 24.1 | | Power of Attorney (incorporated by reference to the signature page of this Registration Statement). | | | | | | | | | | X |
